WG Nanotechnologies for Regenerative Medicine

Nanotechnologies and nanomaterials offer a wide ranges of new possibilities to optimize regenerative medicine, which is the process of replacing, engineering or regenerating human cells, tissues or organs to restore or establish normal function. Nanoparticles and nanofibers may notably act as carriers, targeting elements and/or scaffolds in combination with biomaterials, to trigger better and faster replacement of damaged tissues and organs by stimulating the body’s own repair mechanisms. This ETPN WG acts to promote and facilitate all these applications of nano-enabled regenerative medicines.

Meriem Lamghari

Meriem Lamghari

Group leader at i3S/INEB and Professor at Institute of Biomedical Sciences Abel Salazar of University of Porto

Chairwoman

Lia Rimondini

Lia Rimondini

Full Professor, Head of the the Department of Health Sciences, University of Piemonte Orientale

Vice-chair

Key topics of interest

  • “Smart” nanostructured and functionalised surfaces: functionalisation of 2D-3D materials
  • Scaffolds and nanoparticles for new and advanced therapeutic treatments
  • 3D printing of cells and biomaterials for implants and/or reconstruction
  • Intelligent biomaterials / bioactive materials: site specific delivery of active molecules / nanoparticles with spatial and temporal control over the release of biochemical molecules and/or in vivo activation of stem cells / mimic the morphological, mechanical and biochemical environment of tissues / Biomimetic, biocompatible, biocompetent biomaterials
  • Nanofunctionalisation for increased biocompatibility of implants: polymer coated medical implants to improve biocompatibility

Benefits and challenges of this working group

  • Join the strategic discussions of the WG of the future of R&D in RegMed
  • Participate to the shaping of the next public funding grants in the domain
  • Share your success stories in RegMed
  • Find new R&D partners and/or build your next research consortium in RegMed (H2020, EuroNanoMed III)

Key actions:

Developing any applications in Regenerative medicine?